List of androgens/anabolic steroids available in the United States
This is a complete list of androgens/anabolic steroids (AAS) and formulations that are approved by the FDA and available in the United States. AAS like testosterone are used in androgen replacement therapy (ART), a form of hormone replacement therapy (HRT), and for other indications.
Testosterone and estersEdit
Testosterone (unmodified/non-esterified) is available in the following formulations:
- Topical gels: Androgel, Fortesta, Testim, Testosterone (generic)
- Topical solutions: Axiron, Testosterone (generic)
- Transdermal patches: Androderm, Testoderm (discontinued), Testoderm TTS (discontinued), Testosterone (generic)
- Intranasal gels: Natesto
- Buccal tablets: Striant
- Pellet implants: Testopel
In addition to testosterone itself, the following ester prodrugs of testosterone are available in oil solutions for intramuscular injection:
- Testosterone cypionate (Depo-Testosterone, Testosterone Cypionate (generic))
- Testosterone enanthate (Delatestryl, Testosterone Enanthate (generic))
- Testosterone undecanoate (Aveed)
Testosterone propionate was previously available but was discontinued. A combination of testosterone cypionate and estradiol cypionate (brand name Depo-Testadiol) and a combination of testosterone enanthate and estradiol valerate (brand name Ditate-DS) were also formerly available as oil solutions for intramuscular injection, but these formulations have been discontinued as well.
Oral, buccal, and/or sublingualEdit
- Fluoxymesterone (Android-F, Halotestin, Ora-Testryl)
- Methyltestosterone (Android 5, Android 10, Android 25, Metandren, Oreton, Oreton Methyl, Testred, Virilon)
- Oxandrolone (Oxandrin)
- Oxymetholone (Anadrol-50)
(Note that while the above AAS remain available in at least one formulation, many of the above-listed brand names have been discontinued.)
- Nandrolone decanoate (Deca-Durabolin)
Weakly androgenic progestinsEdit
The following progestins are weakly androgenic and have been associated with androgenic side effects in women:
Ethisterone (Pranone) was previously available but was discontinued.
- John E. Morley; Lucretia van den Berg (5 November 1999). Endocrinology of Aging. Springer Science & Business Media. pp. 141–. ISBN 978-1-59259-715-4.
- Carrie Bagatell; William J. Bremner (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 144–. ISBN 978-1-59259-388-0.
- "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 16 November 2016.